Nestlé Is Using AI to Design Foods for People on Wegovy and Mounjaro

Nestlé has started using artificial intelligence to build food and supplement products for people taking weight loss drugs like Wegovy and Mounjaro. The company confirmed this to Reuters. In fact, the approach says a lot about where the food industry is heading as GLP-1 receptor agonists reshape how millions of people eat.

Stefan Palzer is Nestlé’s chief technical officer. He explained how it works. Essentially, company scientists feed AI systems huge amounts of clinical research data. From there, they design products that respond to real physical changes in patients’ bodies.

One issue Nestlé is tackling head-on is something people call “Ozempic face.” This happens when rapid weight loss causes the face to lose fat quickly. As a result, skin can end up looking hollow or aged. To address this, Nestlé’s answer involves adding collagen protein to products under its Vital Products wellness line.

Muscle loss is another problem Palzer flagged. Indeed, people on GLP-1 drugs often lose significant lean muscle mass along with fat. That’s not just the weight they’re trying to shed. Consequently, Nestlé says it found a combination of two micronutrients that help muscle tissue rebuild faster. Protein handles one side of the equation, while these micronutrients push the muscle to regenerate.

Given this, it helps to understand why muscle loss happens in the first place. GLP-1 receptor agonists mimic a hormone that controls appetite and slows digestion. Accordingly, doctors prescribe these drugs only under medical supervision. That’s largely because of gastrointestinal side effects and metabolic shifts. Moreover, rapid weight loss on these medications tends to strip away muscle disproportionately. Therefore, doctors and dietitians have flagged this as a genuine long-term health concern, not just a cosmetic one.

Nestlé isn’t stopping at side effects during treatment, however. The company is also filing patents for ingredients meant to curb appetite after patients stop taking these drugs. This matters because weight regain after stopping GLP-1 medication is extremely common. Once the drug leaves the body, the hormonal signals that suppressed appetite disappear too. As a result, old eating patterns often return.

It’s worth noting, meanwhile, that these products haven’t been evaluated by the FDA for any medical claims. Instead, Nestlé is positioning them as nutritional support, not treatment. Nevertheless, marketing claims tied to weight management outcomes would likely draw attention from federal advertising and labeling regulators. This is especially true given how closely the cost of GLP-1 therapy is already scrutinized by patients and insurers.

This move fits into a much bigger pattern at Nestlé. In November 2025, for instance, the company joined Microsoft and Harvard’s Frontier Firm AI Initiative. That expanded AI’s role into recipe development, supply chain efficiency, and sustainability work. That same month, Nestlé also gave all 271,000 employees access to Microsoft’s Copilot Chat assistant. Today, around 100,000 workers use AI tools daily.

Then, in July 2026, Nestlé announced a 563 million Swiss franc investment, roughly $688 million. Specifically, the money is going toward a new Nescafé production and distribution facility in Thailand. According to the company, AI-driven smart manufacturing will keep the facility running efficiently.

Meanwhile, type 2 diabetes and obesity prescriptions keep climbing across the US. As a result, food companies face real pressure to fill the nutritional gaps these drugs create. In this light, Nestlé’s strategy shows how consumer brands are starting to treat drug side effects as product opportunities. Ultimately, whether regulators view these AI-designed foods as closer to therapeutic products, rather than ordinary groceries, is a question likely to come up soon.